MA56391B1 - Agonistes du récepteur du peptide de type glucagon 1 - Google Patents
Agonistes du récepteur du peptide de type glucagon 1Info
- Publication number
- MA56391B1 MA56391B1 MA56391A MA56391A MA56391B1 MA 56391 B1 MA56391 B1 MA 56391B1 MA 56391 A MA56391 A MA 56391A MA 56391 A MA56391 A MA 56391A MA 56391 B1 MA56391 B1 MA 56391B1
- Authority
- MA
- Morocco
- Prior art keywords
- glucagon
- peptide
- receptor agonists
- compound
- formula
- Prior art date
Links
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868117P | 2019-06-28 | 2019-06-28 | |
| PCT/US2020/038617 WO2020263695A1 (en) | 2019-06-28 | 2020-06-19 | Glucagon-like peptide 1 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA56391A MA56391A (fr) | 2022-05-04 |
| MA56391B1 true MA56391B1 (fr) | 2023-11-30 |
Family
ID=80781601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA56391A MA56391B1 (fr) | 2019-06-28 | 2020-06-19 | Agonistes du récepteur du peptide de type glucagon 1 |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR119173A1 (es) |
| MA (1) | MA56391B1 (es) |
-
2020
- 2020-06-17 AR ARP200101699A patent/AR119173A1/es unknown
- 2020-06-19 MA MA56391A patent/MA56391B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR119173A1 (es) | 2021-12-01 |
| MA56391A (fr) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210337A1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| HRP20191614T1 (hr) | Spojevi koji su suagonisti gip i glp-1 | |
| NZ740644A (en) | Glucagon receptor agonists | |
| MY197569A (en) | Gip/glp1 co-agonist compounds | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| MA39247A1 (fr) | 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque | |
| MA43468A1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| MX2022001137A (es) | Compuestos agonistas de gipr. | |
| TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
| CO5150232A1 (es) | METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2] | |
| EA201170305A1 (ru) | Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу | |
| CO5150222A1 (es) | METODO Y COMBINACION QUE UTILIZAN (- )NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2] | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| AR045173A1 (es) | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio | |
| MA34885B1 (fr) | Analogues du glucagon presentant una ctivite de recepteur de gip | |
| EA202092269A1 (ru) | Модуляторы сопряженных с g-белком рецепторов | |
| MA41138B1 (fr) | Formulation à rapport fixe d'insuline glargine/lixisenatide | |
| DK1888103T3 (da) | Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering | |
| MA38534A1 (fr) | Compositions synergiques comprenant le (2s)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl)ethoxy)phenyl)propanoate et des agents, par ex. Inhibiteurs de dipeptidyl peptidase-4, biguanide et/ou statines pour une utilisation dans la dyslipidémie | |
| EA201890524A1 (ru) | (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака | |
| Santin et al. | Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions | |
| MA53711A (fr) | Antagonistes de récepteur alpha 2-adrénergiques de sous-type c (alpha-2c) pour le traitement de l'apnée du sommeil | |
| MA56391B1 (fr) | Agonistes du récepteur du peptide de type glucagon 1 |